HeartBeam (NASDAQ: BEAT) announced the launch of a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, known as ischemia. The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (“MCT”) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam’s technology aims to fill a critical gap.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could provide clinicians with a powerful tool for earlier detection and monitoring of coronary artery disease.”
The pilot study will evaluate the patch’s ability to detect ischemia, which is often a precursor to heart attacks. If successful, the technology could enable more proactive management of cardiovascular disease, potentially reducing the number of sudden cardiac events. The study comes as the seriousness of coronary artery disease continues to intensify with aging populations and increasing cardiovascular risk factors.
Investors and industry observers are watching closely as HeartBeam advances its product toward commercialization. The company’s newsroom provides the latest updates and news relating to BEAT at https://ibn.fm/BEAT. For full terms of use and disclaimers, please visit http://IBN.fm/Disclaimer.
